Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Bioventus Inc (BVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: BVS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15
1 Year Target Price $15
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 77.67% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 496.97M USD | Price to earnings Ratio 46.38 | 1Y Target Price 15 |
Price to earnings Ratio 46.38 | 1Y Target Price 15 | ||
Volume (30-day avg) 3 | Beta 0.79 | 52 Weeks Range 5.81 - 11.59 | Updated Date 12/12/2025 |
52 Weeks Range 5.81 - 11.59 | Updated Date 12/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.8% | Operating Margin (TTM) 8.13% |
Management Effectiveness
Return on Assets (TTM) 4.14% | Return on Equity (TTM) 6.38% |
Valuation
Trailing PE 46.38 | Forward PE 8.83 | Enterprise Value 782743577 | Price to Sales(TTM) 0.88 |
Enterprise Value 782743577 | Price to Sales(TTM) 0.88 | ||
Enterprise Value to Revenue 1.39 | Enterprise Value to EBITDA 8.46 | Shares Outstanding 66976477 | Shares Floating 33302044 |
Shares Outstanding 66976477 | Shares Floating 33302044 | ||
Percent Insiders 11.71 | Percent Institutions 74.39 |
Upturn AI SWOT
Bioventus Inc
Company Overview
History and Background
Bioventus Inc. was founded in 2012 as a spin-off from Smith & Nephew's Biologics Division. It focuses on developing and commercializing orthobiologic solutions. Since its inception, it has grown through product development and acquisitions to address unmet needs in musculoskeletal health.
Core Business Areas
- Active Healing Therapies: This segment focuses on products that promote bone and tissue healing, including bone graft substitutes, cartilage repair therapies, and ultrasonic bone healing systems.
- Pain Relief Therapies: This segment includes hyaluronic acid (HA) injections for osteoarthritis pain relief and other pain management products.
Leadership and Structure
Kenneth Reali is the CEO. The company operates with a functional organizational structure, with departments dedicated to R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- DUROLANE: A single-injection hyaluronic acid (HA) product for osteoarthritis pain relief. The HA market is competitive with companies like Sanofi (SNY), Seikagaku Corp, and Fidia Farmaceutici S.p.A. Bioventus is a significant player in this market. Revenue numbers are not publicly broken out per product but it's a key driver of revenue.
- EXOGEN: An ultrasound bone healing system used to accelerate the healing of fractures. Competitors include Orthofix (OFIX) and Zimmer Biomet (ZBH). Market share data is not publicly broken out per product.
- OSTEOAMP: A family of bone graft substitute products that contains viable bone cells to enhance bone growth and fusion. Competitors include Medtronic (MDT) and Stryker (SYK). Revenue numbers are not publicly broken out per product.
Market Dynamics
Industry Overview
The orthobiologics market is growing due to an aging population, increasing prevalence of musculoskeletal disorders, and demand for less invasive treatments. Technological advancements and regenerative medicine are also driving growth.
Positioning
Bioventus is positioned as a leader in orthobiologics, offering a portfolio of products for bone healing, pain management, and joint preservation. Its competitive advantage lies in its established brand, distribution network, and innovative product pipeline.
Total Addressable Market (TAM)
The global orthobiologics market is estimated to be in the billions of dollars annually. Bioventus is positioned to capture a significant share of this market through its diverse product portfolio and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diverse product portfolio
- Established distribution network
- Innovative product pipeline
- Experienced management team
Weaknesses
- High R&D expenses
- Reliance on key products
- Competition from larger players
- Vulnerability to regulatory changes
Opportunities
- Expanding into new markets
- Developing new products
- Acquiring complementary businesses
- Partnering with other companies
Threats
- Increased competition
- Pricing pressure
- Product liability claims
- Changes in reimbursement policies
- Economic downturn
Competitors and Market Share
Key Competitors
- SNY
- OFIX
- ZBH
- MDT
- SYK
Competitive Landscape
Bioventus competes with larger medical device companies and specialized orthobiologics firms. Its competitive advantage lies in its focus on innovation and its portfolio of differentiated products.
Major Acquisitions
Misonix Inc
- Year: 2021
- Acquisition Price (USD millions): 518
- Strategic Rationale: Expanded Bioventus's surgical and regenerative medicine offerings and broadened its customer base.
Growth Trajectory and Initiatives
Historical Growth: Bioventus had grown through organic product sales and strategic acquisitions.
Future Projections: Future projections are not publicly available, as Bioventus was recently taken private.
Recent Initiatives: Recent strategic initiatives included new product launches and expansion into new geographic markets. The sale of the company and going private is a major initiative.
Summary
Bioventus is a leading orthobiologics company with a diverse product portfolio and a strong brand. The company faces competition from larger players and must manage R&D expenses effectively. However, it has opportunities to expand into new markets and develop innovative products. The company was taken private to allow it to make changes outside the glare of being publicly traded.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Bioventus Inc. Investor Relations
- Industry reports
- Company press releases
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and analyst estimates. Actual results may vary. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioventus Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2021-02-11 | President, CEO & Director Mr. Robert E. Claypoole | ||
Sector Healthcare | Industry Medical Devices | Full time employees 950 | Website https://www.bioventus.com |
Full time employees 950 | Website https://www.bioventus.com | ||
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.